Skip to content
Screener

Novavax NVAX Return on equity

Discontinued — last reported Q1 '22

Return on equity at other companies

Moderna logo
ModernaMRNA
-39%+28.0pp
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
-30.6%+37.9pp
Merck & Co. logo
Merck & Co.MRK
7%-28.5pp
ALN
Alnylam PharmaceuticalsALNY
91.4%—
Roivant Sciences logo
Roivant SciencesROIV
-17.1%-17.7pp
Gilead Sciences logo
Gilead SciencesGILD
-20.6%-53.8pp

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.27B+3.7%
Enterprise value$1.38B+33.6%
P/S3.1×+1.9×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Debt / equity1.5×—
Current ratio2.3×0.0×

Where this comes from

Calculated from Novavax’s reported figures.

net income/total stockholders equity=-238.6%

Based on trailing twelve months.

The source filing: Novavax’s 10-Q, filed May 10, 2022. Open the filing →

Filed
May 9, 2022, 7:11 PM EDT
Fiscal quarter
Q1 FY2022
Calendar quarter
Q1 2022
Accession
0001000694-22-000009

FAQ

What is Novavax's return on equity?
Novavax (NVAX) reported return on equity of -238.6% in Q1 2022.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Ask your AI about Novavax's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude